News

COPENHAGEN, Denmark and BOSTON, U.S., January 8, 2026 – Muna Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced it has been awarded a $1 million research grant from the Alzheimer’s Association to support its ongoing Phase 1 trial of MNA-001—a novel potent, selective and orally administered small molecule, in healthy young and elderly subjects—and its work to identify and validate translational biomarkers of the function and activation of triggering receptor expressed on myeloid cells 2 (TREM2) in the context of Alzheimer’s disease.

COPENHAGEN, Denmark, November 10, 2025 – Muna Therapeutics, a clinical stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced that the first subjects have been dosed in a Phase 1 single-ascending dose/multiple-ascending dose study of lead asset MNA-001 in healthy adult participants. MNA-001 is a novel potent, selective and orally administered small molecule “triggering receptor expressed on myeloid cells 2” (TREM2) agonist with best-in-class potential for the treatment of early Alzheimer’s and other neurodegenerative diseases.

Copenhagen, Denmark, December 5, 2024 –Muna Therapeutics (Muna), a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced a research alliance with GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. The companies will explore insights from Muna’s MiND-MAP platform, which applies spatial transcriptomics to brain samples from Alzheimer’s disease patients, cognitively resilient individuals, healthy controls, and centenarians with and without cognitive impairment. This unique dataset of exceptional breadth and resolution will fuel the discovery and development of innovative medicines for Alzheimer's disease.